Efficacy of Assisted Reproductive Technology in Women with Liver Disease, with Tatyana Kushner, MD, BSCE


We sat down with Tatyana Kushner, MD, BSCE to discuss findings from her study comparing IVF treatment in women with and without liver disease.

Women with liver disease experiencing impaired fertility may benefit from treatment with assisted reproductive technology, with findings from a retrospective study showing similar in vitro fertilization (IVF) treatment and pregnancy outcomes among patients with and without liver disease.

The study included women with liver disease who underwent IVF, embryo biopsy for genetic testing, and embryo cryopreservation at a high-volume fertility practice from 2002 to 2021, as well as a subanalysis of patients who subsequently underwent a single embryo transfer with a thawed euploid embryo. Women without liver disease who received assisted reproductive technology treatment due to male factor infertility were additionally enrolled in the study as controls.

The final study population included 115 women with liver disease who underwent 186 IVF cycles and 624 control patients who underwent 868 IVF cycles with embryo biopsy for genetic testing. Compared to the control group, patients with liver disease had a significantly lower number of oocytes retrieved (12.3 vs 16.5; P < .05), number of mature oocytes (9.1 vs 12.6; P < .05), number of fertilized embryos (7.0 vs 9.9; P < .05), number of embryos biopsied (3.4 vs 5.1; P < .05), and number of euploid embryos (1.6 vs 2.7; P < .05).

Despite these differences, investigators observed similar mature oocyte rates, fertilization per mature oocyte rates, and embryo ploidy rates between the liver disease and control groups. Of note, liver disease was not found to be significantly associated with any of these outcomes on univariable and multivariable linear regression analyses.

Investigators pointed out similar trends for single embryo transfer, with no significant differences in rates of clinical pregnancy (70.3% vs 65.5%; P = .55), clinical pregnancy loss (7.1% vs 8.8%, P = .76), or live birth (64.9% vs 58.6%, P = .45) observed between liver disease and control patients. Again, liver disease was not found to be significantly associated with any of these outcomes.

For further insight into the study’s results and their clinical significance, the editorial team of HCPLive Hepatology sat down with Tatyana Kushner, MD, BSCE, associate professor of medicine in the division of liver diseases at the Icahn School of Medicine at Mount Sinai.

Brooks, A. Assisted Reproductive Technology Outcomes Unaffected By Presence of Liver Disease. January 3, 2024. Accessed January 4, 2024. https://www.hcplive.com/view/assisted-reproductive-technology-outcomes-unaffected-by-presence-of-liver-disease

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.